Should I buy or sell aTyr Pharma stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for aTyr Pharma in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" LIFE shares. View LIFE analyst ratings or view top-rated stocks .

What is aTyr Pharma's stock price target for 2024?

4 brokerages have issued 12-month target prices for aTyr Pharma's shares. Their LIFE share price targets range from $16.00 to $35.00. On average, they anticipate the company's share price to reach $23.67 in the next twelve months. This suggests a possible upside of 1,379.2% from the stock's current price. View analysts price targets for LIFE or view top-rated stocks among Wall Street analysts .

How have LIFE shares performed in 2024?

aTyr Pharma's stock was trading at $1.41 at the beginning of 2024. Since then, LIFE stock has increased by 13.5% and is now trading at $1.60. View the best growth stocks for 2024 here .

Are investors shorting aTyr Pharma?

aTyr Pharma saw a increase in short interest in March. As of March 31st, there was short interest totaling 436,900 shares, an increase of 51.0% from the March 15th total of 289,300 shares. Based on an average daily volume of 540,800 shares, the short-interest ratio is currently 0.8 days. View aTyr Pharma's Short Interest .

When is aTyr Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our LIFE earnings forecast .

How were aTyr Pharma's earnings last quarter?

aTyr Pharma, Inc. (NASDAQ:LIFE) issued its earnings results on Thursday, March, 14th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.23) by $0.02.

When did aTyr Pharma's stock split?

aTyr Pharma shares reverse split on Monday, July 1st 2019. The 1-14 reverse split was announced on Friday, June 28th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 28th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What is Sanjay Shukla, M.D, M.S's approval rating as aTyr Pharma's CEO?

3 employees have rated aTyr Pharma Chief Executive Officer Sanjay Shukla, M.D, M.S on Glassdoor.com . Sanjay Shukla, M.D, M.S has an approval rating of 100% among the company's employees. This puts Sanjay Shukla, M.D, M.S in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of aTyr Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other aTyr Pharma investors own include Wynn Resorts (WYNN) , Biocept (BIOC) , SCYNEXIS (SCYX) , Idera Pharmaceuticals (IDRA) , OPKO Health (OPK) , Precigen (PGEN) , QUALCOMM (QCOM) , Sorrento Therapeutics (SRNE) , Viking Therapeutics (VKTX) and Aldeyra Therapeutics (ALDX) .

When did aTyr Pharma IPO?

aTyr Pharma (LIFE) raised $76 million in an initial public offering on Thursday, May 7th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Citigroup served as the underwriters for the IPO and BMO Capital Markets and William Blair were co-managers.

Who are aTyr Pharma's major shareholders?

aTyr Pharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include Kingswood Wealth Advisors LLC (0.09%). Insiders that own company stock include Jill Marie Broadfoot , John K Clarke , Paul Schimmel and Sanjay Shukla . View institutional ownership trends .

How do I buy shares of aTyr Pharma?

Shares of LIFE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:LIFE

aTyr Pharma (LIFE) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free LIFE Stock Alerts

$1.60

-0.02 (-1.23%)

(As of 04/19/2024 ET)

Compare

Today's Range: $1.58
▼
$1.65
50-Day Range: $1.59
▼
$2.02
52-Week Range: $1.08
▼
$2.70

Volume: 159,073 shs
Average Volume: 514,669 shs
Market Capitalization: $108.71 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $23.67

Get aTyr Pharma alerts:

aTyr Pharma MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.75 Rating Score
Upside/Downside: 1,379.2% Upside
$23.67 Price Target
Short Interest: Healthy
0.64% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.70
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.97) to ($1.03) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.96 out of 5 stars

Medical Sector

582nd out of 911 stocks

Biological Products, Except Diagnostic Industry

94th out of 150 stocks

3.4

Analyst's Opinion

Consensus Rating
aTyr Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
aTyr Pharma has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.64% of the outstanding shares of aTyr Pharma have been sold short.
Short Interest Ratio / Days to Cover
aTyr Pharma has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in aTyr Pharma has recently increased by 51.02%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
aTyr Pharma does not currently pay a dividend.
Dividend Growth
aTyr Pharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for LIFE.

3.2

News and Social Media Coverage

News Sentiment
aTyr Pharma has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for aTyr Pharma this week, compared to 1 article on an average week.
Search Interest
Only 8 people have searched for LIFE on MarketBeat in the last 30 days. This is a decrease of -11% compared to the previous 30 days.
MarketBeat Follows
6 people have added aTyr Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, aTyr Pharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.70% of the stock of aTyr Pharma is held by insiders.
Percentage Held by Institutions
61.72% of the stock of aTyr Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for aTyr Pharma are expected to decrease in the coming year, from ($0.97) to ($1.03) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of aTyr Pharma is -1.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of aTyr Pharma is -1.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
aTyr Pharma has a P/B Ratio of 1.04. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About aTyr Pharma Stock (NASDAQ:LIFE)

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

LIFE Stock Price History

30 days | 90 days | 365 days | Advanced Chart

LIFE Stock News Headlines

April 17, 2024 | msn.com

Atal Incubation Centre - Centre for Cellular and Molecular Biology signs agreement with Thermo Fisher Scientific to advance innovation in India

April 17, 2024 | americanbankingnews.com

aTyr Pharma (NASDAQ:LIFE) Stock Price Crosses Above 200 Day Moving Average of $1.54

April 20, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

April 1, 2024 | finance.yahoo.com

aTyr Pharma to Participate in April Investor Conferences

April 1, 2024 | globenewswire.com

aTyr Pharma to Participate in April Investor Conferences

March 26, 2024 | investorplace.com

3 Penny Stocks That Could Be Multibaggers in the Making: March Edition

March 18, 2024 | msn.com

3 Best Stocks to Buy Now, 3/18/2024, According to Top Analysts

March 17, 2024 | finanznachrichten.de

aTyr Pharma, Inc.: aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update

April 20, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

March 16, 2024 | benzinga.com

Recap: aTyr Pharma Q4 Earnings

March 16, 2024 | finance.yahoo.com

aTyr Pharma Full Year 2023 Earnings: Revenues Disappoint

March 15, 2024 | markets.businessinsider.com

Buy Rating Affirmed for aTyr Pharma as Lead Candidate efzofitimod Advances in Clinical Trials with Solid Financial Footing

March 15, 2024 | finance.yahoo.com

aTyr Pharma Inc (LIFE) Reports Full Year 2023 Financial Results and Corporate Progress

March 15, 2024 | finance.yahoo.com

Q4 2023 aTyr Pharma Inc Earnings Call

March 15, 2024 | finance.yahoo.com

aTyr Pharma, Inc. (NASDAQ:LIFE) Q4 2023 Earnings Call Transcript

March 14, 2024 | investorplace.com

LIFE Stock Earnings: aTyr Pharma Misses EPS for Q4 2023

March 14, 2024 | washingtonpost.com

Atyr Pharma: Q4 Earnings Snapshot

March 14, 2024 | globenewswire.com

aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update

March 14, 2024 | msn.com

Options Volatility and Implied Earnings Moves Today, March 14, 2024

March 13, 2024 | benzinga.com

aTyr Pharma's Earnings Outlook

March 13, 2024 | markets.businessinsider.com

aTyr Pharma is about to announce earnings — here's what Wall Street expects

February 28, 2024 | globenewswire.com

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results

February 23, 2024 | finance.yahoo.com

We Think aTyr Pharma (NASDAQ:LIFE) Can Afford To Drive Business Growth

February 21, 2024 | finance.yahoo.com

aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants

February 21, 2024 | globenewswire.com

aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants

February 15, 2024 | investorplace.com

The 3 Best Penny Stocks to Buy in February 2024

February 9, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: aTyr Pharma (LIFE), CVS Health (CVS) and Science 37 (SNCE)

See More Headlines

Receive LIFE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for aTyr Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/14/2024
Today: 4/20/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: Life Sciences Tools & Services
Current Symbol: NASDAQ:LIFE
CUSIP: 53217V10
CIK: 1339970
Web: www.atyrpharma.com
Phone: (858) 731-8389
Fax: 858-731-8394
Employees: 56
Year Founded: 2005

Price Target and Rating

Average Stock Price Target: $23.67
High Stock Price Target: $35.00
Low Stock Price Target: $16.00
Potential Upside/Downside: +1,379.2%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.75
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.96)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-50,390,000.00
Net Margins: N/A
Pretax Margin: -14,276.77%
Return on Equity: -49.84%
Return on Assets: -39.12%

Debt

Debt-to-Equity Ratio: 0.02
Current Ratio: 6.27
Quick Ratio: 6.27

Sales & Book Value

Annual Sales: $353,000.00
Price / Sales: 307.95
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.54 per share
Price / Book: 1.04

Miscellaneous

Outstanding Shares: 67,941,000
Free Float: 65,427,000
Market Cap: $108.71 million
Optionable: Optionable
Beta: 1.25

Social Links

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

Dr. Sanjay S. Shukla M.D. (Age 52)
M.S., President, CEO & Director
Comp: $795.48k
Ms. Jill M. Broadfoot (Age 62)
Chief Financial Officer
Comp: $556.62k
Ms. Nancy E. Denyes Krueger (Age 56)
General Counsel & Corporate Secretary
Comp: $532.13k
Xiang-Lei Yang Ph.D.
Founder
Ms. Ashlee Dunston
Director of Investor Relations & Corporate Communications
Mr. Peter Villiger
Vice President of Corporate Development
Ms. Danielle Campbell
VP of Human Resource
Dr. Leslie Nangle Ph.D.
Vice President of Research
Dr. Ying J. Buechler Ph.D.
Executive Director of Biologics Development & Manufacturing
Dr. David J. King Ph.D. (Age 65)
Scientific Consultant
Comp: $327.31k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

LIFE Stock Analysis - Frequently Asked Questions

Should I buy or sell aTyr Pharma stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for aTyr Pharma in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" LIFE shares.
View LIFE analyst ratings or view top-rated stocks.
What is aTyr Pharma's stock price target for 2024?: 4 brokerages have issued 12-month target prices for aTyr Pharma's shares. Their LIFE share price targets range from $16.00 to $35.00. On average, they anticipate the company's share price to reach $23.67 in the next twelve months. This suggests a possible upside of 1,379.2% from the stock's current price.
View analysts price targets for LIFE or view top-rated stocks among Wall Street analysts.
How have LIFE shares performed in 2024?: aTyr Pharma's stock was trading at $1.41 at the beginning of 2024. Since then, LIFE stock has increased by 13.5% and is now trading at $1.60.
View the best growth stocks for 2024 here.
Are investors shorting aTyr Pharma?: aTyr Pharma saw a increase in short interest in March. As of March 31st, there was short interest totaling 436,900 shares, an increase of 51.0% from the March 15th total of 289,300 shares. Based on an average daily volume of 540,800 shares, the short-interest ratio is currently 0.8 days.
View aTyr Pharma's Short Interest.
When is aTyr Pharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our LIFE earnings forecast.
How were aTyr Pharma's earnings last quarter?: aTyr Pharma, Inc. (NASDAQ:LIFE) issued its earnings results on Thursday, March, 14th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.23) by $0.02.

When did aTyr Pharma's stock split?: aTyr Pharma shares reverse split on Monday, July 1st 2019. The 1-14 reverse split was announced on Friday, June 28th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 28th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.
What is Sanjay Shukla, M.D, M.S's approval rating as aTyr Pharma's CEO?: 3 employees have rated aTyr Pharma Chief Executive Officer Sanjay Shukla, M.D, M.S on Glassdoor.com. Sanjay Shukla, M.D, M.S has an approval rating of 100% among the company's employees. This puts Sanjay Shukla, M.D, M.S in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of aTyr Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other aTyr Pharma investors own include Wynn Resorts (WYNN), Biocept (BIOC), SCYNEXIS (SCYX), Idera Pharmaceuticals (IDRA), OPKO Health (OPK), Precigen (PGEN), QUALCOMM (QCOM), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX) and Aldeyra Therapeutics (ALDX).
When did aTyr Pharma IPO?: aTyr Pharma (LIFE) raised $76 million in an initial public offering on Thursday, May 7th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Citigroup served as the underwriters for the IPO and BMO Capital Markets and William Blair were co-managers.
Who are aTyr Pharma's major shareholders?: aTyr Pharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include Kingswood Wealth Advisors LLC (0.09%). Insiders that own company stock include Jill Marie Broadfoot, John K Clarke, Paul Schimmel and Sanjay Shukla.
View institutional ownership trends.
How do I buy shares of aTyr Pharma?: Shares of LIFE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LIFE) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

aTyr Pharma (LIFE) Stock Price, News & Analysis

aTyr Pharma MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About aTyr Pharma Stock (NASDAQ:LIFE)

LIFE Stock Price History

LIFE Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

LIFE Stock Analysis - Frequently Asked Questions

Overall MarketRank^™